

## Recognition Molecules Directed Against hTERT and Use Thereof

### Description

The present invention relates to recognition molecules directed against a gene of a catalytic subunit of human telomerase (hTERT), as well as to the use of said recognition molecules for the diagnosis, prophylaxis, attenuation and follow-up of diseases associated with cell growth, differentiation and/or division, such as tumor diseases.

Replication of the ends of eukaryotic chromosomes is known to require specialized cell components. Replication of a linear DNA strand normally proceeds in 5'-3' direction. When removing the primers bound to the outer 3' end of chromosomal eukaryotic DNA and the enzymes involved, which are co-responsible for replication, a gap is introduced, resulting in a continuous reduction in length of the daughter strands in each replication. Said reduction in length at the chromosome ends is responsible for cell ageing, among other things. The structure of said ends, also referred to as telomeres, has been investigated in numerous living systems. In accordance with the relationship between telomeres and telomerase and the proliferative capability of cells, telomerase activity has been detected in immortalized/immortal cell lines and in various types of tumor tissue. Furthermore, there is a well-known relationship between the level of telomerase activity in a tumor and the clinical course of the tumor disease. Therefore, human telomerase is an ideal target in the diagnosis and treatment of human diseases associated with cellular proliferation, such as cancer. *Inter alia*, methods for the diagnosis and treatment of cancer and other diseases associated with telomerase have been disclosed in US 5,489,508 or US

5,645,986. Inhibition of telomerase has been described as a specific means for the therapeutic control of tumor cells. Important efforts in modifying the activity of telomerase in association with cancerous diseases have been disclosed in EP 666 313, WO 97/37691 or WO 98/28442. However, the above general teachings do not disclose any concrete teachings as to technical activity to a person skilled in the art. While a substance or a molecule interacting with the entire region of a telomerase will result in a reduction of the corresponding activity, e.g. in a cell culture, such substances, however, are not suitable for application in organisms because they are normally too large in size, being attacked and destroyed by the immune system of the respective organism. The object of the invention was therefore to provide alternative, compact molecules that would undergo facile and effectively inhibiting interaction with selected specific structural units encoding telomerase.

The invention solves the above technical problem by providing a recognition molecule directed against an mRNA of the catalytic subunit of human telomerase, said recognition molecule undergoing specific interaction particularly with primary structures of the catalytic subunit of human telomerase mRNA in a target sequence region of from 2000 to 2500 according to the gene data base entry AF 015950. Hence, the invention relates to the unexpected teaching that tumor-associated abnormal hTERT mRNA expression patterns and telomerase activity levels can be counteracted by possible hTERT inhibition using the recognition molecules according to the invention. Said recognition molecules are directed against well-defined mRNA sequence motifs in a range of from 2000 to 2500. They may represent biological and/or chemical structures capable of interacting with the target sequence region in such a way that interaction can be determined. More specifically, examples of recognition molecules are nucleic acid constructs, lectins or antibodies.

In a preferred embodiment of the invention the recognition molecule interacts with a target sequence region of from 2100 to 2400. This region is advantageous to achieve hTERT inhibition.

In another preferred embodiment of the invention the recognition molecule interacts with a target sequence region of from 2190 to 2360. Advantageously, very good hTERT inhibition can be achieved in this region.

In a particularly preferred embodiment the recognition molecule interacts specifically with the target sequence regions of from 2191 to 2224 and/or from 2318 to 2346. Advantageously, particularly efficient hTERT inhibition is possible in the above sequence regions.

Owing to these preferred target sequence regions, it is possible for a person skilled in the art to provide, in particular, very small and/or compact recognition molecules which essentially do not interact with or are not affected by other structures, particularly structures of immunologic defense, within the cell tissue or the organism, but instead are capable of specifically interacting with the target sequence region of the catalytic subunit of human telomerase mRNA.

Another preferred embodiment of the invention envisages that the sequence region or the recognition molecule be modified by addition, amplification, inversion, missense mutation, nonsense mutation, point mutation, deletion and/or substitution. In the recognition molecule, for example, the above modifications may result in binding thereof to the catalytic subunit with higher avidity or specificity. Obviously, however, it may also be envisaged that the recognition molecule binds with lower specificity or avidity. In the meaning of the invention, the mutations in the

sequence region can be heritable or non-heritable changes, for example. The modifications can be such in nature that detection thereof is possible directly on the mRNA level or on the DNA level. For example, the mutations may also include mutations in connection with cytologically visible genome and/or chromosome mutations associated with changes of the hTERT. Such mutations may originate in such a way that portions of the chromosome are lost, doubled, present in reversed orientation, or transferred on other chromosomes. Of course, such a mutation may involve only one or a few adjacent base pairs, as is the case in a point mutation, for example. If, for example, a base pair is lost in the form of a deletion, or if a base pair is interposed in addition, as in insertion, the reading frame of the respective gene will be shifted to form a reading frame mutation, in particular. For example, in a substitution mutation in the meaning of the invention, one base is replaced by another, in which case the resulting consequences may be different:

- (a) one codon may be converted into a synonymous codon, for example; or
- (b) the mutation changes the codon specificity, resulting in incorporation of other amino acids; or
- (c) the mutation causes termination of translation at a particular position, in which case the hTERT fragments being formed can be either inactive or active.

In another preferred embodiment of the invention the recognition molecule is immobilized. In the meaning of the invention, immobilization is understood to involve various methods and techniques to fix the recognition molecules on specific carriers. For example, immobilization can serve to stabilize the recognition molecules so that their activity

would not be reduced or adversely modified by biological, chemical or physical exposure, especially during storage or in single-batch use. Immobilization of the recognition molecules allows repeated use under technical or clinical routine conditions; furthermore, the sample can be reacted with the recognition molecules in a continuous fashion. In particular, this can be achieved by means of various immobilization techniques, with binding of the recognition molecules to other recognition molecules or molecules or to a carrier proceeding in such a way that the three-dimensional structure in the active center of the corresponding molecules, especially of said recognition molecules, would not be changed. Advantageously, there is no loss in specificity to the catalytic subunit of human telomerase and in specificity of the actual binding reaction as a result of such immobilization. In the meaning of the invention, three basic methods can be used for immobilization:

- (i) Crosslinking: in crosslinking, the recognition molecules are fixed to one another without adversely affecting their activity. Advantageously, they are no longer soluble as a result of crosslinking.
- (ii) Binding to a carrier: binding to a carrier proceeds via adsorption, ionic binding or covalent binding, for example. Such binding may also take place inside microbial cells or liposomes or other membranous, closed or open structures. Advantageously, the recognition molecule is not adversely affected by such fixing. For example, carrier-bound multiple or continuous use thereof is possible with advantage in clinics in diagnosis or therapy.

- (iii) Inclusion: inclusion in the meaning of the invention especially is inclusion in a semipermeable membrane in the form of gels, fibrils or fibers. Advantageously, encapsulated recognition molecules are separated from the surrounding sample solution by a semipermeable membrane in such a way that interaction with the catalytic subunit of human telomerase or with fragments thereof still is possible.

Various methods are available for immobilization, such as adsorption on an inert or electrically charged inorganic or organic carrier. For example, such carriers can be porous gels, aluminum oxide, bentonite, agarose, starch, nylon or polyacrylamide. Immobilization proceeds via physical binding forces, frequently involving hydrophobic interactions and ionic binding. Advantageously, such methods are easy to handle, having little influence on the conformation of the recognition molecules. Advantageously, binding can be improved as a result of electrostatic binding forces between the charged groups of the recognition molecules and the carrier, e.g. by using ion exchangers such as Sephadex. Another method is covalent binding to carrier materials. In addition, the carriers may have reactive groups forming homopolar bonds with amino acid side chains. Suitable groups in recognition molecules are carboxy, hydroxy and sulfide groups and especially the terminal amino groups of lysines. Aromatic groups offer the possibility of diazo coupling. The surface of microscopic porous glass particles can be activated by treatment with silanes and subsequently coated with recognition molecules. For example, hydroxy groups of natural polymers can be activated with bromocyanogen and subsequently coupled with recognition molecules. Advantageously, a large number of recognition molecules can undergo direct covalent binding with polyacrylamide resins. Inclusion in three-dimensional networks involves inclusion

of the recognition molecules in ionotropic gels or other structures well-known to those skilled in the art. More specifically, the pores of the matrix are such in nature that the recognition molecules are retained, allowing interaction with the target molecules. In crosslinking, the recognition molecules are converted into polymer aggregates by crosslinking with bifunctional agents. Such structures are gelatinous, easily deformable and, in particular, suitable for use in various reactors. By adding other inactive components such as gelatin in crosslinking, advantageous improvement of mechanical and enzymatic properties is possible. In microencapsulation, the reaction volume of the recognition molecules is restricted by means of membranes. For example, microencapsulation can be carried out in the form of an interfacial polymerization. Owing to the immobilization during microencapsulation, the recognition molecules are made insoluble and thus reusable. In the meaning of the invention, immobilized recognition molecules are all those recognition molecules being in a condition that allows reuse thereof. Restricting the mobility and solubility of the recognition molecules by chemical, biological or physical means advantageously results in lower process cost.

In another preferred embodiment the recognition molecule is a nucleic acid construct, a chelator, a lectin and/or an antibody. Nucleic acid constructs in the meaning of the invention can be all structures based essentially on nucleic acids, or wherein the active center is based essentially on nucleic acids. Of course, the entire construct can predominantly be constituted of lipids, carbohydrates or proteins/peptides, e.g. in the form of a nanocapsule, and said construct may comprise a region containing nucleic acids capable of interacting with the catalytic subunit of human telomerase. Various ways of providing such constructs are well-known to those skilled in the art. A chelator in the

meaning of the invention is a collective term for cyclic compounds where metals, groups having unshared electron pairs or electron deficiency, and hydrogen are involved in ring formation, and which are capable of interacting specifically with the catalytic subunit of human telomerase mRNA. Particularly advantageous are coordination compounds of metals, which can be referred to as metal chelators in the meaning of the invention. They are compounds wherein a single ligand occupies more than one coordination sites on a central atom, i.e., is at least bidentate. In this event, compounds normally being linear are closed by complex formation via a metal atom or ion to form rings, which rings are capable of interacting specifically with the catalytic subunit of human telomerase mRNA. In particular, a lectin in the meaning of the invention is a phytohemagglutinin, frequently a vegetable protein, which, owing to its high affinity to particular components, can undergo specific binding and agglutination on the surface of particular nucleic acid structures. More specifically, lectins interact with sugar structures which can be associated with specific sequence regions of a nucleic acid. An antibody in the meaning of the invention specifically binds the above-mentioned target regions. The antibodies can also be modified antibodies (e.g. oligomers, reduced, oxidized and labelled antibodies). The term antibody as used in the present specification encompasses both intact molecules and antibody fragments which bind particular determinants of the target region. In these fragments the antibody's capability of selective binding is retained in part, the fragments being defined as follows:

- (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be generated by cleavage of a whole antibody using the enzyme papain, thereby obtaining an intact light chain and part of a heavy chain;



- (2) the Fab' fragment of an antibody molecule can be produced by treatment of a whole antibody with pepsin and subsequent reduction, thereby obtaining an intact light chain and part of a heavy chain; two Fab' fragments per antibody molecule are obtained;
- (3)  $F(ab')_2$ , the fragment of the antibody, which can be obtained by treatment of a whole antibody with the enzyme pepsin without subsequent reduction;  $F(ab')_2$  is a dimer of two Fab' fragments held together by two disulfide bonds;
- (4) Fv, defined as a fragment modified by genetic engineering, which includes the variable region of the light chain and the variable region of the heavy chain and is expressed in the form of two chains; and
- (5) single-chain antibody (SCA), defined as a molecule modified by genetic engineering, which includes the variable region of the light chain and the variable region of the heavy chain linked by a suitable polypeptide linker to form a genetically fused single-chain molecule.

The term epitope used in the present invention represents a particular target region of a gene of a catalytic subunit of human telomerase, which is formed in such a way that an antibody is capable of undergoing specific interaction with the same.

In a preferred embodiment of the invention the nucleic acid construct is an antisense (AS) oligonucleotide, a DNAzyme, a ribozyme, an siRNA and/or a peptide nucleic acid (PNA).

AS constructs are synthetically produced oligonucleotides allowing selective inhibition of the biosynthesis of se-

lected proteins. For example, oligodeoxynucleotides (ODN), peptide nucleic acids (PNA), ribozymes, DNazymes are employed. The AS effect is based on sequence-specific hybridization of the constructs through Watson-Crick base pairing with the target mRNA encoding the protein to be repressed, resulting in prevention of protein synthesis via various mechanisms (Table 1).

**Table 1: AS effects and their mechanisms of action**

ss: single-stranded

Effect	Mechanism	References
Inhibition of transcription	Binding of the AS constructs to genomic DNA by Hoogsten triplex formation	[Moser et al.]
Modulation of RNA processing	a) blocking of splicing sites results in prevention of the splicing process b) prevention of polyadenylation destabilizes the mRNA c) obstruction of mRNA transport into the cytoplasm	[Kole et al., Crooke]
Inhibition of translation	Competitive binding of the AS construct to the target mRNA prevents initiation or elongation process	[Boiziau et al.]
Cleavage of target mRNA	a) selective degradation of the RNA strand in RNA-DNA hybrids by RNase H endonuclease b) degradation of ss-RNA by RNase L endonuclease after activation by 2',5'-tetraadenylate-modified ODN c) ribozyme/DNAzyme-catalyzed, sequence-specific cleavage of target mRNA	[Crooke, Agrawal et al., Sun et al.]

Apart from other fields of application, the development of antisense oligonucleotides (AS-ODNs) as therapeutic substances also represents a new promising therapeutic concept for oncologic diseases. While conventional chemotherapy results in non-specific inhibition of cell proliferation, the

antisense therapy very specifically inactivates those mRNAs which represent the molecular basis or an essential component of degenerate, deregulated growth and tumor progression and may be responsible for the inhibition of the endogenous immune defense.

Antisense oligonucleotides (AS-ODNs) differ from other therapeutic agents, such as antibodies, toxins or immunotoxins, in that they are relatively small molecules with a molecular weight of normally about 5 kDa. The small size of the AS-ODNs allows good tissue penetration. Furthermore, tumor blood vessels, as opposed to blood vessels of normal tissues, are known to be permeable to substances ranging in size between 4 to 10 kDa. Consequently, therapeutic AS-ODNs are capable of penetrating tumor blood vessels in a well-directed fashion. Another advantage of these substances, e.g. with respect to antibodies almost exclusively effective against extracellular proteins, is that all proteins, in principle, i.e. cytoplasmic and membranous, as well as proteins located in the nucleus, can be attacked via the respective target mRNA.

At present, phosphothioate AS-ODNs relatively resistant to nuclease attack are being evaluated with respect to their potential as anti-cancer therapeutic agents in a number of clinical studies (phase I-III), with overexpressed targets in tumors being attacked.

When using phosphothioate oligonucleotides (PS-ODN), a number of unexpected, so-called "non-AS" effects have been observed which, in addition, give rise to non-specific inhibition of cell growth. These effects strongly depend on the ODN sequence or on specific sequence motifs, occurring due to strong polyanionic charge of the PS-ODNs, which may result in binding of the PS-ODNs to vital proteins. The negative effects mentioned above can be overcome by using the

so-called second generation AS-ODNs (mixed backbone ODNs). One positive side effect observed when using PS-ODNs is their immunostimulatory effect which can be quite useful in supporting possible therapeutic success in some tumor applications.

Being catalytically active RNA molecules, ribozymes are capable of recognizing cellular RNA structures as substrates, cleaving them at a phosphodiester bond in a sequence-specific fashion. Recognition proceeds via AS branches which, owing to complementary sequences, allow hybridization with the target mRNA. Compared to AS-ODNs, ribozymes have the fundamental advantage that a ribozyme molecule, being a true catalyst, is capable of reacting a large number of identical substrate molecules. Consequently, ribozymes are effective at substantially lower concentrations compared to ODNs and, in addition, lead to irreversible RNA degradation as a result of substrate cleavage [Sun et al.].

Amongst the types of ribozymes known to date, the hammerhead ribozyme (Review: Birikh et al., 1997; Tanner, 1999) is particularly interesting for such uses because it has catalytic activity even as a comparatively small molecule (about 30-50 nucleotides). For example, a highly effective trans-cleaving hammerhead ribozyme consists of no more than 14 conserved nucleotides in the catalytic domain and two variable ancestral sequences (each advantageously made up of 6 to 8 nucleotides) which, via Watson-Crick base pairing (in analogy to antisense ODN), accomplish sequence-specific recognition of the substrate to be cleaved, subsequently inactivating the latter by cleavage of a phosphodiester bond. In this fashion, it is possible to construct a specifically cleaving hammerhead ribozyme for virtually any RNA molecule having a potential cleavage site with the minimum sequence requirement -NUX- and thus inhibit e.g. cellular mRNA or viral RNA.

RNAi (RNA interference) is a new methodology allowing specific gene inhibition of target molecules on an mRNA level. To this end, double-stranded RNA molecules (small interference RNA, siRNA) with their 3' overhangs two nucleotides in length, preferably consisting of thymidine nucleotides, must be transfected into cells. Initially, the siRNA constructs are associated with specific cellular proteins, followed by recognition of the target mRNA sequence on the basis of the complementarity of the antisense siRNA strand. The intrinsic endonuclease activity of the ribonucleoprotein complex allows specific degradation of the mRNA to be inhibited.

In one distinctive embodiment of the invention the antisense oligonucleotide (AS-ODN) is a phosphothioate antisense oligonucleotide or a mixed-backbone oligonucleotide (for a review see Agrawal and Kandimalla 2000). They are ODN constructs partially modified or completely protected by such chemical modification. More specifically, terminal modification of ODN constructs (preferably 2-5 bonds of the 3' and 5' nucleic acid terminus are modified) offers improved stability in *in vivo* application and in the extra- and intracellular medium of target cells (in particular, protection from exonuclease degradation).

In another preferred embodiment of the invention the sequence region of the hTERT mRNA, to which the recognition molecule is complementary, is selected from the group comprising 2183-2205, 2206-2225, 2315-2334, 2324-2346, 2317-2336, 2331-2350 and/or 2333-2352.

Advantageously, these sequence regions permit inhibition of the activity of a gene of a catalytic subunit of human telomerase. *Inter alia*, said inhibition allows suppression of diseases associated with the activity of said gene, such as tumors.

The invention also relates to a pharmaceutical composition comprising the recognition molecules of the invention, optionally in combination with a pharmaceutically tolerable carrier. More specifically, the pharmaceutical carrier may comprise additional materials and substances such as medical and/or pharmaceutical-technical adjuvants. For example, medical adjuvants are materials used as ingredients in the production of pharmaceutical compositions. Pharmaceutical-technical adjuvants serve to suitably formulate the drug or pharmaceutical composition and, if required during the production process only, can even be removed thereafter, or they can be part of the pharmaceutical composition as pharmaceutically tolerable carriers. Formulation of the pharmaceutical composition is optionally effected in combination with a pharmaceutically tolerable diluent. For example, the diluents can be phosphate-buffered saline, water, emulsions such as oil/water emulsions, various types of detergents, sterile solutions, and the like. The pharmaceutical composition can be administered in association with a gene therapy, for example, using e.g. viral vectors or/and complex formation with lipids or dendrimers. The kind of dosage and route of administration can be determined by the attending physician according to clinical requirements. As is familiar to those skilled in the art, the kind of dosage will depend on various factors, such as size, body surface, age, sex, or general and pathognomonic health condition of the patient, but also on the particular agent being administered, the time period and type of administration, and on other medications possibly administered in parallel, especially in a combination therapy.

The invention also relates to a kit comprising the recognition molecule and/or the pharmaceutical composition. Furthermore, the invention also relates to an array comprising the recognition molecule and/or the pharmaceutical composition. Kit and array can be used in the diagnosis and/or

therapy of diseases associated with the function of the catalytic subunit of human telomerase. The invention also relates to the use of said recognition molecule, said kit, said array in the diagnosis, prophylaxis, reduction, therapy, follow-up and/or aftercare of diseases associated with cell growth, differentiation and/or division.

In a preferred embodiment the disease associated with cell growth, differentiation and/or division is a tumor. In a particularly preferred fashion the tumor is a solid tumor and/or a leukemia.

More specifically, the tumors in the meaning of the invention can be the following types of cancer: adenocarcinoma of breast, prostate and colon; all forms of lung cancer starting in the bronchial tube; bone marrow cancer, melanoma, hepatoma, neuroblastoma; papilloma; apudoma, choris-toma, branchioma; malignant carcinoid syndrome; carcinoid heart disease, carcinoma (for example, Walker carcinoma, basal cell carcinoma, squamobasal carcinoma, Brown-Pearce carcinoma, ductal carcinoma, Ehrlich tumor, *in situ* carcinoma, cancer-2 carcinoma, Merkel cell carcinoma, mucous cancer, non-parvicellular bronchial carcinoma, oat-cell carcinoma, papillary carcinoma, scirrhus carcinoma, bronchio-alveolar carcinoma, bronchial carcinoma, squamous cell carcinoma and transitional cell carcinoma); histiocytic functional disorder; leukemia (e.g. in connection with B cell leukemia, mixed-cell leukemia, null cell leukemia, T cell leukemia, chronic T cell leukemia, HTLV-II-associated leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, mast cell leukemia, and myeloid leukemia); malignant histiocytosis, Hodgkin disease, non-Hodgkin lymphoma, solitary plasma cell tumor; reticuloendotheliosis, chondroblastoma; chondroma, chondrosarcoma; fibroma; fibrosarcoma; giant cell tumors; histiocytoma; lipoma; liposarcoma; leukosarcoma; mesothelioma; myxoma; myxosarcoma; osteoma; os-



teosarcoma; Ewing sarcoma; synovioma; adenofibroma; adenolymphoma; carcinosarcoma, chordoma, craniopharyngioma, dysgerminoma, hamartoma; mesenchymoma; mesonephroma, myosarcoma, ameloblastoma, cementoma; odontoma; teratoma; thymoma, chorioblastoma; adenocarcinoma, adenoma; cholangioma; cholesteatoma; cylindroma; cystadenocarcinoma, cystadenoma; granulosa cell tumor; gynadrioblastoma; hidradenoma; islet-cell tumor; Leydig cell tumor; papilloma; Sertoli cell tumor, theca cell tumor, leiomyoma; leiomyosarcoma; myoblastoma; myoma; myosarcoma; rhabdomyoma; rhabdomyosarcoma; ependymoma; ganglioneuroma, glioma; medulloblastoma, meningioma; neurilemmoma; neuroblastoma; neuroepithelioma, neurofibroma, neuroma, paraganglioma, non-chromaffin paraganglioma, angiokeratoma, angiolymphoid hyperplasia with eosinophilia; sclerotizing angioma; angiomatosis; glomangioma; hemangioendothelioma; hemangioma; hemangiopericytoma, hemangiosarcoma; lymphangioma, lymphangiomyoma, lymphangiosarcoma; pinealoma; cystosarcoma phylloides; hemangiosarcoma; lymphangiosarcoma; myxosarcoma, ovarian carcinoma; sarcoma (for example, Ewing sarcoma, experimentally, Kaposi sarcoma and mast cell sarcoma); neoplasms (for example, bone neoplasms, breast neoplasms, neoplasms of the digestive system, colorectal neoplasms, liver neoplasms, pancreas neoplasms, hypophysis neoplasms, testicle neoplasms, orbital neoplasms, neoplasms of the head and neck, of the central nervous system, neoplasms of the hearing organ, pelvis, respiratory tract and urogenital tract); neurofibromatosis and cervical squamous cell dysplasia.

In another preferred embodiment the cancerous disease or tumor being treated or prevented is selected from the group of: tumors of the ear-nose-throat region, comprising tumors of the inner nose, nasal sinus, nasopharynx, lips, oral cavity, oropharynx, larynx, hypopharynx, ear, salivary glands, and paragangliomas, tumors of the lungs, comprising non-parvicellular bronchial carcinomas, parvicellular bron-

chial carcinomas, tumors of the mediastinum, tumors of the gastrointestinal tract, comprising tumors of the esophagus, stomach, pancreas, liver, gallbladder and biliary tract, small intestine, colon and rectal carcinomas and anal carcinomas, urogenital tumors comprising tumors of the kidneys, ureter, bladder, prostate gland, urethra, penis and testicles, gynecological tumors comprising tumors of the cervix, vagina, vulva, uterine cancer, malignant trophoblast disease, ovarian carcinoma, tumors of the uterine tube (Tuba Fallopii), tumors of the abdominal cavity, mammary carcinomas, tumors of the endocrine organs, comprising tumors of the thyroid, parathyroid, adrenal cortex, endocrine pancreas tumors, carcinoid tumors and carcinoid syndrome, multiple endocrine neoplasias, bone and soft-tissue sarcomas, mesotheliomas, skin tumors, melanomas comprising cutaneous and intraocular melanomas, tumors of the central nervous system, tumors during infancy, comprising retinoblastoma, Wilms tumor, neurofibromatosis, neuroblastoma, Ewing sarcoma tumor family, rhabdomyosarcoma, lymphomas comprising non-Hodgkin lymphomas, cutaneous T cell lymphomas, primary lymphomas of the central nervous system, Hodgkin's disease, leukemias comprising acute leukemias, chronic myeloid and lymphatic leukemias, plasma cell neoplasms, myelodysplasia syndromes, paraneoplastic syndromes, metastases with unknown primary tumor (CUP syndrome), peritoneal carcinomatosis, immunosuppression-related malignancy comprising AIDS-related malignancies such as Kaposi sarcoma, AIDS-associated lymphomas, AIDS-associated lymphomas of the central nervous system, AIDS-associated Hodgkin disease, and AIDS-associated anogenital tumors, transplantation-related malignancy, metastasized tumors comprising brain metastases, lung metastases, liver metastases, bone metastases, pleural and pericardial metastases, and malignant ascites.

In a distinctive embodiment of the invention the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

In another particularly preferred embodiment of the invention it is envisaged that the tumor is a colon carcinoma, stomach carcinoma, pancreas carcinoma, a colon cancer, small intestine cancer, an ovarian carcinoma, cervical carcinoma, a lung cancer, a renal cell carcinoma, a brain tumor, a head-throat tumor, a liver carcinoma and/or a metastase of the above tumors/carcinomas.

In another particularly preferred embodiment the solid tumor is a mammary, bronchial, colorectal and/or prostate carcinoma.

In a most preferred embodiment the tumor of the urogenital tract is a bladder carcinoma. In the Federal Republic of Germany, bladder carcinoma (BCa) represents the fourth most frequent form of cancer and the seventh most frequent cause of cancer death in males. TUR-B as a general primary therapy of BCa allows organ-preserving removal of superficial tumors. Despite such histopathologically defined complete removal of the tumor, a relatively high percentage of patients, being from 50 to 70%, experience a relapse within two years [Stein et al.]. One problem in diagnosis and therapy is the synchronous or metachronous multifocal appearance of tumor centers, which may be a possible cause of the appearance of relapses remote from the resected primary tumor location [Sidransky et al.]. In cases of appearing relapses or tumors primarily classified as superficial, the TUR-B is normally followed by a long-term prophylaxis using an immunotherapeutic (bacillus Calmette Guérin; BCG) or chemotherapeutic agent (e.g. mitomycin C, taxol, gemcitabin/cisplatin). Patients with muscle-invasive BCa and dedifferentiated superficial tumors, who experience relapse

despite such therapy, are normally treated with radical cystectomy or, preserving the bladder, by means of mono-/polychemo-, immuno- or radiotherapy or combined procedures of these methods. Due to their relatively unspecific mechanisms of action, chemical, immune or radiation treatments are accompanied by high therapy-induced toxicity.

Due to the importance of bladder carcinoma in health policy (especially in Western industrial nations), lack of tumor-specific markers, and well-known tumor-biological and cellular heterogeneity of the tumor, there is an intense search in the field of clinical research on bladder carcinoma, particularly with the aim of identifying new or/and supplementing therapeutic options.

In a distinctive embodiment of the invention the recognition molecule, the pharmaceutical composition, the kit and/or the array are used in a follow-up essentially representing monitoring the effectiveness of an anti-tumor treatment. Furthermore, it is preferred that the recognition molecule be used in a combination therapy, especially for the treatment of tumors. In a particularly preferred fashion, said combination therapy comprises a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy. In a particularly preferred embodiment of the invention the combination therapy is an adjuvant, biologically specific form of therapy, and in a particularly preferred fashion, said form of therapy is an immune therapy. Furthermore, in a particularly preferred fashion the combination therapy comprises a gene therapy and/or a therapy using a recognition molecule thereof or other target molecule. Various combination therapies, especially for the treatment of tumors, are well-known to those skilled in the art. For example, a treatment with cytostatic agents or e.g. irradiation of a particular tumor area can be envisaged within the scope of a combination therapy, and this treatment is com-

bined with a gene therapy, using the recognition molecule of the invention as an anticancer agent. However, the recognition molecule according to the invention can also be used in combination with other recognition molecules directed against the same target molecule or a different structure. Accordingly, the use of the recognition molecule for increasing the sensitivity of tumor cells to cytostatic agents and/or radiation can be particularly preferred. Furthermore, a preferred use of the recognition molecule is in inhibiting the vitality, the proliferation rate of cells and/or inducing apoptosis and cell cycle arrest.

Without intending to be limiting, the invention will be explained in more detail with reference to an example.

#### **Example**

Following transfection, especially when using five specific anti-hTERT-AS constructs (see Table 2), the easily transfectable human bladder carcinoma cell line EJ28 showed immediate and continuous reduction of its viability by more than 65% compared to the nonsense control. It was remarkable to observe that four of the most effective constructs were directed against one single mRNA sequence motif.

After four of five treatments with the construct AStel2331-50, virtually no living cells could be detected anymore. In contrast, treatment of telomerase-negative human fibroblasts gave no significant differences between antisense and nonsense ODN-treated cells, thus indirectly proving specificity of the AS-ODN effect on the BCa cell line EJ28 (data not shown). AS-specific efficacy was subsequently investigated in detail: in accordance with the viability test, an inhibiting effect of the five AS-ODNs with respect to proliferation and cell colony-forming behavior could be demonstrated (Fig. 4). Moreover, AS-specific reduction of

the cell percentage in the DNA synthesis phase (up to about 30%) towards G1 arrest could be detected (data not shown). Evidence of the AS-specific effect of the AS-ODNs directed against the target motifs was furnished in the form of a significant and time-dependent reduction of the hTERT transcript level (Fig. 3). Correspondingly, there was also a repression of the hTERT protein expression. Furthermore, as a result thereof, the telomerase activity of the EJ28 cells was inhibited by more than 60% (data not shown). On the whole, it was possible to demonstrate that the most effective AS constructs are based on one single-stranded motif of the hTERT mRNA.

**Table 2:**

**hTERT-AS and NS-ODN: nucleotide and target sequences**

Designation <sup>1</sup>	ss motif <sup>2</sup>	Sequence <sup>3</sup> (5' → 3')
AS-ODN		
ASel2206-2225	2191-2224	tgtcctgggggat <b>ggtg</b> tcg
ASel2315-2334	2318-2346	<b>ttgaagg</b> ccttgcggaacgtg
ASel2317-2336		tctt <b>gaagg</b> ccttgcggaacg
ASel2331-2350		ggtagagacgtggct <b>cttga</b>
ASel2333-2352		aaggtagagacgtggct <b>ctt</b>
NS-ODN		
NS-K2	-	cagtctcagtactgaagctg
NS-K3		cagcttcagtactgagactg

<sup>1</sup> The designation includes the sequence region of the hTERT mRNA (Acc. No.: AF015950) to which the respective AS-ODN is complementary.

<sup>2</sup> Each ss motif extended by 10 nt in 5' and 3' direction.

<sup>3</sup> The nucleotides in bold type represent the AS-ODN region which is complementary to the actual ss region of the target motif.

**Claims:**

1. A recognition molecule directed against a gene of a catalytic subunit of human telomerase, characterized in that the recognition molecule specifically interacts with the catalytic subunit of human telomerase mRNA in a target sequence region of from 2000 to 2500 in accordance with accession number AF015950.
2. The recognition molecule according to claim 1, characterized in that the recognition molecule specifically interacts with the target sequence region of from 2100 to 2400.
3. The recognition molecule according to claim 1 or 2, characterized in that the recognition molecule specifically interacts with the target sequence region of from 2190 to 2360.
4. The recognition molecule according to any of claims 1 to 3, characterized in that the recognition molecule specifically interacts with the target sequence region of from 2191 to 2224 and/or from 2318 to 2346.
5. The recognition molecule according to any of claims 1 to 4, characterized in that the sequence region and/or the recognition molecule is modified by addition, amplification, inversion, mis-sense mutation, nonsense mutation, point mutation, deletion and/or substitution.

6. The recognition molecule according to any of claims 1 to 5,  
characterized in that  
the recognition molecule is immobilized.
7. The recognition molecule according to any of claims 1 to 6,  
characterized in that  
the recognition molecule is a nucleic acid construct, a chelator, a lectin and/or an antibody.
8. The recognition molecule according to claim 7,  
characterized in that  
the nucleic acid construct is an antisense oligonucleotide, a DNAzyme, a peptide nucleic acid, a ribozyme and/or an siRNA.
9. The recognition molecule according to claim 8,  
characterized in that  
the antisense oligonucleotide is a phosphothioate antisense oligonucleotide.
10. The recognition molecule according to any of claims 1 to 9,  
characterized in that  
the sequence region of the hTERT mRNA, to which the recognition molecule is complementary, is selected from the group comprising 2183-2205, 2206-2225, 2315-2334, 2324-2346, 2317-2336, 2331-2350 and/or 2333-2352.
11. A pharmaceutical composition comprising a recognition molecule according to any of claims 1 to 10, optionally in combination with a pharmaceutically tolerable carrier.



12. A kit comprising a recognition molecule according to any of claims 1 to 10 and/or a pharmaceutical composition according to claim 11.
13. An array comprising a recognition molecule according to any of claims 1 to 10 and/or a pharmaceutical composition according to claim 11.
14. Use of a recognition molecule according to any of claims 1 to 10, a kit according to claim 12 and/or an array according to claim 13 in the diagnosis, prophylaxis, attenuation, therapy, follow-up and/or aftercare of diseases associated with cell growth, differentiation and/or division.
15. The use according to the preceding claim, characterized in that the disease is a tumor.
16. The use according to the preceding claim, characterized in that the tumor is a solid tumor or a leukemia.
17. The use according to the preceding claim, characterized in that the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.
18. The use according to claim 15, characterized in that the tumor is a colon carcinoma, stomach carcinoma, pancreas carcinoma, a large bowel cancer, a small intestine cancer, an ovarian carcinoma, cervical carcinoma, a lung cancer, a renal cell carcinoma, a brain tumor, a head-throat tumor, a liver carcinoma and/or a metastase of the above tumors.

19. The use according to claim 15,  
characterized in that  
the solid tumor is a mammary, bronchial, colorectal  
and/or prostate carcinoma and/or a metastase of the  
above tumors.
20. The use according to claim 17,  
characterized in that  
the tumor of the urogenital tract is a bladder carci-  
noma and/or a metastase of said tumor.
21. The use according to claim 14,  
characterized in that  
the follow-up is monitoring the effectiveness of an  
anti-tumor treatment.
22. The use according to any of claims 14 to 21,  
characterized in that  
the recognition molecule is used in a combination ther-  
apy.
23. The use according to the preceding claim,  
characterized in that  
the combination therapy comprises a chemotherapy, a  
treatment with cytostatic agents and/or a radiotherapy.
24. The use according to the preceding claim,  
characterized in that  
the combination therapy is an adjuvant biologically  
specified form of therapy.
25. The use according to the preceding claim,  
characterized in that  
said form of therapy is an immune therapy.

26. The use according to any of claims 22 to 25,  
characterized in that  
the combination therapy is a gene therapy and/or a  
therapy using a recognition molecule thereof or other  
target molecule.
27. The use according to any of claims 14 to 23 for in-  
creasing the sensitivity of tumor cells to cytostatic  
agents and/or radiation.
28. Use of a molecule according to any of claims 1 to 10  
for inhibiting the vitality, the proliferation rate of  
cells to induce apoptosis and/or cell cycle arrest.

**Abstract:**

The present invention relates to recognition molecules directed against a gene of a catalytic subunit of human telomerase, as well as to the use of said recognition molecules for the diagnosis, prophylaxis, attenuation and follow-up of diseases associated with cell growth, differentiation and/or division, such as tumor diseases.




Fig. 1

AS-ODN against local secondary structures of the hTERT-mRNA

Two opposite ss structures (2201-14 and 2328-36 nt) are shown, with four AS-ODNs being directed against each one.






Fig. 2

Influence of multiple anti-hTERT treatments with various AS-ODNs on the viability of EJ28 cells



**Fig. 3**

Effects of two AS-ODN transfections on the colony-forming behavior of EJ28 cells



**Fig. 4**

Relative expression level of AS-ODN-treated EJ28 cells